Onyx Gold Corp Stock Price Today (NSE: ONYX)
Fundamental Score
Onyx Gold Corp Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Onyx Gold Corp share price today is ₹45.05, up +2.50% on NSE/BSE as of 3 August 2026. Onyx Gold Corp (ONYX) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹68.36 (Cr). The 52-week high for ONYX share price is ₹46.45 and the 52-week low is ₹28.10. The company has a Return on Equity (ROE) of -0.38% and a debt-to-equity ratio of 0.27.
Onyx Gold Corp Share Price Chart — NSE/BSE Historical Performance
Onyx Gold Corp share price chart: 3.49% return over the past month. 52-week high ₹46.45, 52-week low ₹28.10.
Onyx Gold Corp — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹42.70 | ₹44.80 | ₹42.70 | ₹42.95 | 1.72L (Cr) | |
| ₹44.90 | ₹44.90 | ₹44.10 | ₹44.90 | 4.64L (Cr) | |
| ₹42.80 | ₹42.80 | ₹42.80 | ₹42.80 | 8.00K (Cr) | |
| ₹40.80 | ₹40.80 | ₹40.80 | ₹40.80 | 14.00K (Cr) | |
| ₹35.20 | ₹37.05 | ₹35.20 | ₹37.05 | 6.00K (Cr) | |
| ₹36.25 | ₹37.00 | ₹36.25 | ₹36.45 | 6.00K (Cr) | |
| ₹37.60 | ₹37.60 | ₹37.60 | ₹37.60 | 4.00K (Cr) | |
| ₹38.00 | ₹38.00 | ₹38.00 | ₹38.00 | 2.00K (Cr) | |
| ₹38.60 | ₹38.60 | ₹37.70 | ₹37.70 | 4.00K (Cr) | |
| ₹43.55 | ₹43.55 | ₹41.40 | ₹41.40 | 1.60L (Cr) |
Onyx Gold Corp — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹41.65 | ₹44.90 | ₹35.20 | ₹42.95 | +3.12% | |
| ₹38.00 | ₹38.00 | ₹38.00 | ₹38.00 | +0.00% | |
| ₹35.05 | ₹36.05 | ₹29.00 | ₹32.50 | -7.28% | |
| ₹34.00 | ₹34.00 | ₹32.25 | ₹32.70 | -3.82% | |
| ₹30.60 | ₹32.20 | ₹30.40 | ₹32.20 | +5.23% | |
| ₹37.05 | ₹40.50 | ₹34.85 | ₹35.10 | -5.26% | |
| ₹40.00 | ₹40.00 | ₹33.30 | ₹35.00 | -12.50% | |
| ₹34.80 | ₹37.00 | ₹28.10 | ₹35.10 | +0.86% | |
| ₹39.90 | ₹43.15 | ₹36.20 | ₹38.95 | -2.38% | |
| ₹42.00 | ₹44.75 | ₹37.75 | ₹40.50 | -3.57% | |
| ₹44.55 | ₹46.45 | ₹42.00 | ₹42.00 | -5.72% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Onyx Gold is a drill-or-die exploration play in the Timmins Gold Camp.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Pre-scraped news indicates mixed sentiment, with US market headwinds potentially denting India pharma earnings. Alembic Pharma and Sun Pharma had positive news with FDA nod and a precedent-setting ruling, respectively.
CORE STORY (THE REAL GAME)
- Exploration upside at Munro-Croesus
- TSX Venture 50 recognition
- Positive gold price outlook
- New high-grade gold discoveries
- Positive resource estimate updates
- Takeover offer from a major mining company
- Micro-cap liquidity risk
- Exploration risk: no guarantee of success
- Dilution risk: further capital raises likely
FII down 3.41%.
Indian pharmaceutical exports are projected to grow, reaching $130 billion by 2030.
No: Free Cash Flow 5Y: ₹None Cr
Onyx needs to deliver exploration success in the next 3-6 months to justify its valuation. Watch for drilling updates from Munro-Croesus.
Primary Thesis Risk
Exploration failure will lead to a significant value destruction.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Onyx Gold Corp Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Onyx Gold Corp Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ONYX across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Conservative Debt Levels (D/E: 0.27)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (65.10%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (-0.38%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (1.14%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-64.97%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Interest Coverage (0.65x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-32.35 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 3.46%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Onyx Gold Corp vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Onyx Gold Corp with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
14.7/100 | ₹45.05₹45 | ₹68.36₹68.36 | — — | -0.38%Poor -0.38% Poor | 1.14%Poor 1.14% Poor | 0.27Excellent 0.3 Excellent | — — | — — | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Onyx Gold Corp Quarterly Performance
Latest quarterly metrics for ONYX — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
9.69%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-64.97%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Onyx Gold Corp Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ONYX — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Onyx Gold Corp Financial Statements
Annual income statement, balance sheet and cash flow for Onyx Gold Corp (ONYX) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Onyx Gold Corp
About ONYX (Onyx Gold Corp)
Onyx Gold Corp (ONYX) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current mar...ket capitalisation of ₹68.36 (Cr). Onyx Gold Corp has delivered a Return on Equity (ROE) of -0.38% and a ROCE of 1.14%. The debt-to-equity ratio stands at 0.27, reflecting the company's capital structure. Investors tracking ONYX share price can monitor key metrics including P/E ratio, promoter holding of 65.10%, and quarterly earnings growth.
Company Details
ONYX Share Price: Frequently Asked Questions
What is the current share price of Onyx Gold Corp?
Onyx Gold Corp (ONYX) trades at ₹45.05 on NSE. Market cap ₹68.36 (Cr). Educational data only.
What is the P/E ratio of Onyx Gold Corp?
Onyx Gold Corp has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Onyx Gold Corp?
Onyx Gold Corp has a Bull Run score of 14.7/100 based on 25+ financial parameters.
Does Onyx Gold Corp pay dividends?
Onyx Gold Corp has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Onyx Gold Corp?
Onyx Gold Corp has ROE of -0.38%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Onyx Gold Corp?
Onyx Gold Corp has debt-to-equity of 0.27.
Is Onyx Gold Corp a good investment?
Bull Run gives Onyx Gold Corp a score of 14.7/100. This is not investment advice — consult a SEBI-registered advisor.